Altimmune (0A4C) Financial Statements
Altimmune Financial Overview
Altimmune's market cap is currently $396.82M. The company's EPS TTM is $-0.78; its P/E ratio is -2.62; Altimmune is estimated to report earnings on November 10, 2026, and the estimated EPS forecast is $-0.13. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 41.00K | $ 20.00K | $ 426.00K | $ -68.00K | $ 4.41M |
| Gross Profit | $ 41.00K | $ 20.00K | $ 426.00K | $ -68.00K | $ 4.41M |
| Operating Income | $ -94.49M | $ -103.17M | $ -95.93M | $ -87.74M | $ -96.91M |
| EBITDA | $ -87.03M | $ -94.81M | $ -87.94M | $ -84.41M | $ -96.53M |
| Net Income | $ -88.09M | $ -95.06M | $ -88.45M | $ -84.71M | $ -97.09M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 273.46M | $ 131.89M | $ 197.81M | $ 184.88M | $ 190.30M |
| Total Assets | $ 279.93M | $ 139.31M | $ 210.64M | $ 206.93M | $ 218.87M |
| Total Debt | $ 35.69M | $ 1.68M | $ 671.00K | $ 1.12M | $ 1.53M |
| Net Debt | $ -8.07M | $ -35.24M | $ -134.45M | $ -109.97M | $ -188.77M |
| Total Liabilities | $ 55.04M | $ 15.80M | $ 16.54M | $ 21.64M | $ 19.73M |
| Stockholders' Equity | $ 224.89M | $ 123.51M | $ 194.10M | $ 185.29M | $ 199.13M |
| Cash Flow | |||||
| Free Cash Flow | $ -67.55M | $ -79.85M | $ -75.86M | $ -62.71M | $ -90.55M |
| Operating Cash Flow | $ -67.53M | $ -79.85M | $ -75.81M | $ -62.59M | $ -78.24M |
| Investing Cash Flow | $ -132.47M | $ -28.39M | $ 13.73M | $ -73.40M | $ 87.52M |
| Financing Cash Flow | $ 206.84M | $ 10.04M | $ 86.11M | $ 56.78M | $ 65.10M |
Currency in USD